A double-blind placebo-controlled study of fluvoxamine and imipramine in depression

R. A. Dominguez, B. J. Goldstein, A. F. Jacobson, R. M. Steinbook

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Outpatients with major affective disorder, unipolar depressed type (N = 101), were treated in a 4-week placebo-controlled double-blind study, to compare the efficacy and safety of fluvoxamine, a new serotonin reuptake inhibitor antidepressant, with imipramine and placebo. Therapy was initiated at 50 mg/day; thereafter, dosage ranged between 100 and 300 mg/day for both drugs. Results indicate statistically significant efficacy, measured by both patient and physician rating scales, for both active drugs over placebo. Fluvoxamine showed some evidence of earlier onset of action. Anticholinergic side effects were more common in the imipramine-treated patients, while fluvoxamine produced more gastrointestinal distress and insomnia.

Original languageEnglish
Pages (from-to)84-87
Number of pages4
JournalJournal of Clinical Psychiatry
Volume46
Issue number3 I
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Fluvoxamine
Imipramine
Placebos
Depression
Serotonin Uptake Inhibitors
Cholinergic Antagonists
Sleep Initiation and Maintenance Disorders
Mood Disorders
Double-Blind Method
Pharmaceutical Preparations
Antidepressive Agents
Outpatients
Physicians
Safety
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Dominguez, R. A., Goldstein, B. J., Jacobson, A. F., & Steinbook, R. M. (1985). A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. Journal of Clinical Psychiatry, 46(3 I), 84-87.

A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. / Dominguez, R. A.; Goldstein, B. J.; Jacobson, A. F.; Steinbook, R. M.

In: Journal of Clinical Psychiatry, Vol. 46, No. 3 I, 01.01.1985, p. 84-87.

Research output: Contribution to journalArticle

Dominguez, RA, Goldstein, BJ, Jacobson, AF & Steinbook, RM 1985, 'A double-blind placebo-controlled study of fluvoxamine and imipramine in depression', Journal of Clinical Psychiatry, vol. 46, no. 3 I, pp. 84-87.
Dominguez RA, Goldstein BJ, Jacobson AF, Steinbook RM. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. Journal of Clinical Psychiatry. 1985 Jan 1;46(3 I):84-87.
Dominguez, R. A. ; Goldstein, B. J. ; Jacobson, A. F. ; Steinbook, R. M. / A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. In: Journal of Clinical Psychiatry. 1985 ; Vol. 46, No. 3 I. pp. 84-87.
@article{78d2ca1f706b47bbb22a6f61ad531b37,
title = "A double-blind placebo-controlled study of fluvoxamine and imipramine in depression",
abstract = "Outpatients with major affective disorder, unipolar depressed type (N = 101), were treated in a 4-week placebo-controlled double-blind study, to compare the efficacy and safety of fluvoxamine, a new serotonin reuptake inhibitor antidepressant, with imipramine and placebo. Therapy was initiated at 50 mg/day; thereafter, dosage ranged between 100 and 300 mg/day for both drugs. Results indicate statistically significant efficacy, measured by both patient and physician rating scales, for both active drugs over placebo. Fluvoxamine showed some evidence of earlier onset of action. Anticholinergic side effects were more common in the imipramine-treated patients, while fluvoxamine produced more gastrointestinal distress and insomnia.",
author = "Dominguez, {R. A.} and Goldstein, {B. J.} and Jacobson, {A. F.} and Steinbook, {R. M.}",
year = "1985",
month = "1",
day = "1",
language = "English",
volume = "46",
pages = "84--87",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "3 I",

}

TY - JOUR

T1 - A double-blind placebo-controlled study of fluvoxamine and imipramine in depression

AU - Dominguez, R. A.

AU - Goldstein, B. J.

AU - Jacobson, A. F.

AU - Steinbook, R. M.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Outpatients with major affective disorder, unipolar depressed type (N = 101), were treated in a 4-week placebo-controlled double-blind study, to compare the efficacy and safety of fluvoxamine, a new serotonin reuptake inhibitor antidepressant, with imipramine and placebo. Therapy was initiated at 50 mg/day; thereafter, dosage ranged between 100 and 300 mg/day for both drugs. Results indicate statistically significant efficacy, measured by both patient and physician rating scales, for both active drugs over placebo. Fluvoxamine showed some evidence of earlier onset of action. Anticholinergic side effects were more common in the imipramine-treated patients, while fluvoxamine produced more gastrointestinal distress and insomnia.

AB - Outpatients with major affective disorder, unipolar depressed type (N = 101), were treated in a 4-week placebo-controlled double-blind study, to compare the efficacy and safety of fluvoxamine, a new serotonin reuptake inhibitor antidepressant, with imipramine and placebo. Therapy was initiated at 50 mg/day; thereafter, dosage ranged between 100 and 300 mg/day for both drugs. Results indicate statistically significant efficacy, measured by both patient and physician rating scales, for both active drugs over placebo. Fluvoxamine showed some evidence of earlier onset of action. Anticholinergic side effects were more common in the imipramine-treated patients, while fluvoxamine produced more gastrointestinal distress and insomnia.

UR - http://www.scopus.com/inward/record.url?scp=0021982926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021982926&partnerID=8YFLogxK

M3 - Article

C2 - 3918993

AN - SCOPUS:0021982926

VL - 46

SP - 84

EP - 87

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 3 I

ER -